Clinical trials: First Relapse
Platinum-Sensitive Ovarian Cancer in First Relapse
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
MORAb-003-011 is a global, multicenter, double-blind, randomized placebo-controlled study to assess the safety and efficacy of farletuzumab in combination with standard chemotherapy in subjects with low cancer antigen 125 (CA125)…
- Trial name
- NCT02289950
- Testing
- Farletuzumab
- Where
- 68 sites in United States, Belgium and 5 more
- Volunteers
- 332 people
- Sponsor
- Eisai Inc.
Multiple Myeloma
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed…
- Trial name
- NCT04075721
- Testing
- M3258, M3258 20 mg
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
- Trial name
- CheckMate331 (NCT02481830)
- Testing
- Nivolumab, Topotecan, Amrubicin
- Where
- 151 sites in United States, Australia and 23 more
- Volunteers
- 569 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Trial name
- NCT00849667
- Testing
- Farletuzumab, Carboplatin, Taxane
- Where
- 375 sites in United States, Argentina and 28 more
- Volunteers
- 1,100 people
- Sponsor
- Morphotek
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase…
- Trial name
- 20170528 (NCT03541369)
- Testing
- AMG 427
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 64 people
- Sponsor
- Amgen
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
This single arm, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with a taxane as first line therapy in participants with HER2-positive breast cancer who relapsed after neoadjuvant…
- Trial name
- NCT01301729
- Testing
- Docetaxel, Paclitaxel, Trastuzumab
- Where
- 17 sites in China
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Refractory Multiple Myeloma
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy.
- Trial name
- NCT02020941
- Testing
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Attaya Suvannasankha
Recurrent Adult Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML.
- Trial name
- ARMY (NCT02353143)
- Testing
- MEN1112
- Where
- 29 sites in Belgium, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Menarini Group
Leukemia, Acute Lymphoblastic
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse.
- Trial name
- NCT02393859
- Testing
- Blinatumomab, Dexamethasone, Vincrisitne
- Where
- 103 sites in Argentina, Australia and 22 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00634244
- Testing
- alvocidib, mitoxantrone hydrochloride, carboplatin
- Where
- 20 sites in United States, Israel
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
This phase II trial studies how well pioglitazone hydrochloride and tyrosine kinase inhibitor (TKI) therapy works in treating patients with chronic myeloid leukemia (CML) that has come back after a period of improvement…
- Trial name
- NCT02730195
- Testing
- Pioglitazone, Tyrosine Kinase Inhibitor (TKI)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
The goal of this national, multicenter single arm phase II clinical trial is to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or metastatic…
- Trial name
- TRANSCENDER (NCT05744375)
- Testing
- Trastuzumab deruxtecan
- Where
- 19 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Spanish Breast Cancer Research Group
Multiple Myeloma in Relapse
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse
In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome inhibitors and IMIDs).
- Trial name
- TOMMY (NCT01794572)
- Testing
- Total Bone Marrow Irradiation (TBMI) 8 Gy, Total Bone Marrow Irradiation (TBMI) 10 Gy, Total Bone Marrow Irradiation (TBMI): 12 Gy
- Where
- 8 sites in France
- Volunteers
- 13 people
- Sponsor
- Institut Cancerologie de l'Ouest
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or, Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
GIMEMA CLL0809 Study (BendOfa)
In the last ten years there have been significant developments in CLL treatment. The advent of fludarabine, rituximab and the association of chemo-immunotherapy have substantially increased overall response rate, CR rate, time to…
- Trial name
- BendOfa (NCT01244451)
- Testing
- Ofatumumab, Bendamustine
- Where
- 32 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Richter's Transformation
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one…
- Trial name
- SIRRT (NCT02138786)
- Testing
- selinexor
- Where
- 17 sites in United States, Germany and 3 more
- Volunteers
- 27 people
- Sponsor
- Karyopharm Therapeutics Inc
Leukemia
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268242
- Testing
- Gemcitabine Hydrochloride, Mitoxantrone Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- The Cleveland Clinic
Schizophrenia, Schizoaffective Disorder, Depressive Type
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
- Trial name
- APPRAISE (NCT04203056)
- Testing
- Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Los Angeles
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT02675452
- Testing
- AMG 176, Azacitidine, Itraconazole
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi